Abstract
Destruction and remodeling of the extracellular matrix occurs during the formation of new blood vessels that are required for tumor growth. We sought to determine whether gene-therapy mediated in vivo delivery of tissue inhibitor of matrix metalloproteinase-3 (TIMP-3), using retroviral vector-producer cells, could suppress angiogenesis and subsequent tumor growth in a murine neuroblastoma model. Tumor volume 28 days after coinjection of tumor cells with producer cells generating TIMP-3-encoding retroviral vectors was 21% that of controls, as was the mean tumor vascular index, a measure of blood vessel maturity. When tumors were allowed to reach a mean volume of 0.05 cm3 before treatment, their size 2 weeks later was 47% relative to controls; larger tumors were not significantly affected. When producer cells were injected at surgical sites following excision of subcutaneous tumors, local recurrence 14 days later was only 22% in TIMP-3 producer cell treated mice as compared to 71% in controls. Unsuccessful transduction of melanoma cells in situ, another tumor of neural crest origin, resulted in unimpaired tumor growth, despite the fact that these tumors are susceptible to TIMP-3 overexpression, demonstrating the importance of tumor cell transduction in this approach. Thus, retroviral vector-producer cell-mediated in vivo gene transfer of TIMP-3 to tumor cells can significantly restrict tumor-induced angiogenesis and tumor growth. This approach may be an effective adjuvant in the treatment of neuroblastoma and other solid tumors refractory to traditional therapy, although it appears to be most effective in smaller tumors or in the setting of minimal residual disease, and the tumor cells must be susceptible to retroviral vector-mediated transduction.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Curran S, Murray GI . Matrix metalloproteinases. Molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000;36:1621–1630.
Sternlicht MD, Bergers G . Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects. Emerging Ther Targets. 2000;4:609–633.
Matrisian LM . Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990;6:121–125.
Liotta LA, Steeg PS, Stetler-Stevenson WG, et al. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64:327–336.
Murphy G, Docherty AJ . The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol. 1992;7:120–125.
Gomez DE, Alonso DF, Yoshiji H, et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74:111–122.
Blavier L, Henriet P, Imren S, et al. Tissue inhibitors of matrix metalloproteinases in cancer. Ann NY Acad Sci. 1999;878:108–119.
Leco KJ, Khokha R, Pavloff N, et al. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem. 1994;269:9352–9360.
Baker AH, George SJ, Zaltsman AB, et al. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer. 1999;79:1347–1355.
Ahonen M, Baker AH, Kahari VM, et al. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res. 1998;58:2310–2315.
Anand-Apte B, Bao L, Smith R, et al. A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol. 1996;74:853–862.
Anand-Apte B, Pepper MS, Voest E, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3 [see comments]. Invest Ophthalmol Vis Sci. 1997;38:817–823.
Spurbeck WW, Ng CYC, Strom T, et al. Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood. 2002;100:3361–3368.
Short MP, Choi BC, Lee JK, et al. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J Neurosci Res. 1990;27:427–439.
Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med. 1997;3:1354–1361.
Millauer B, Shawver LK, Plate KH, et al. Glioblastoma growth inhibited in vivo by a dominant negative Flk-1 mutant. Nature. 1994;367:576–579.
Strawn LM, McMahon G, App H, et al. Flk-1 as a target for tumor growth inhibition. Cancer Res. 1996;56:3540–3545.
Persons DA, Allay JA, Allay ER, et al. Enforced expression of the GATA-2 transcription factor blocks normal hematopoiesis. Blood. 1999;93:488–499.
Davidoff AM, Leary MA, Ng CYC, et al. Retroviral vector-producer cell mediated angiogenesis inhibition restricts neuroblastoma growth in vivo. Med Ped Oncol. 2000;35:638–640.
Migita M, Medin JA, Pawliuk R, et al. Selection of transduced CD34+ progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors. Proc Natl Acad Sci USA. 1995;92:12075–12079.
Persons DA, Mehaffey MG, Kaleko M, et al. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene. Blood Cells, Mol Dis. 1998;24:167–182.
Yang Y, Vanin EF, Whitt MA, et al. Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein. Hum Gene Ther. 1995;6:1203–1213.
Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8.
Etoh T, Inoue H, Tanaka S, et al. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res. 2001;61:2145–2153.
Acknowledgements
This work was supported by grants from the Assisi Foundation of Memphis 94-000, Grant #IRG-87-008-09 from the American Cancer Society, Cancer Center Support CORE Grant, P30 CA 21765 and American Lebanese Syrian Associated Charities (ALSAC). We thank Dorothy Bush for her assistance with immunohistochemistry.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Spurbeck, W., Ng, C., Vanin, E. et al. Retroviral vector-producer cell-mediated in vivo gene transfer of TIMP-3 restricts angiogenesis and neuroblastoma growth in mice. Cancer Gene Ther 10, 161–167 (2003). https://doi.org/10.1038/sj.cgt.7700577
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700577
Keywords
This article is cited by
-
TIMPs: versatile extracellular regulators in cancer
Nature Reviews Cancer (2017)
-
Inhibition of tumor growth and induction of apoptosis in prostate cancer cell lines by overexpression of tissue inhibitor of matrix metalloproteinase-3
Cancer Gene Therapy (2010)
-
TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis
Oncogene (2006)
-
Introduction of G1 phase arrest in Human Hepatocellular carcinoma cells (HHCC) by APMCF1 gene transfection through the down-regulation of TIMP3 and up-regulation of the CDK inhibitors p21
Molecular Biology Reports (2006)